02 January 2025
02 January 2025
Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.
Innovent will receive an $80m upfront payment and could earn up to $1bn in development and commercial milestones.
Tevimbra is already approved in the US for the treatment of unresectable or metastatic oesophageal squamous cell carcinoma (ESCC).
The application of AI in diagnosing and identifying AD cases could lead to more standardised identification of the condition.
KOLs interviewed by GlobalData stressed the lack of biologic therapies specifically targeting T2-low asthma.
The completion of the sale is expected by the end of the first quarter of 2025.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
